Velicept Therapeutics
Malvern
About Velicept Therapeutics
Velicept Therapeutics, Inc. is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs. Its lead program, solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS). Velicept is a portfolio company of NeXeption. For more information,
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1,001 – 5,000
- Estimated revenue: $1K – $10K
- Total funding: $42.0M
- Funding stage: Early Stage Venture
- Last round: Debt Financing (Nov 2019)
- Website: velicept.com
- Phone: (484)318-2988
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Canonical: https://fsome.com/organization/velicept-therapeutics-96324 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.